FDA says its safety review of abortion pill will continue into next year
Headline from WHEC Rochester
The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year. The FDA gave a court-ordered update on its progress in a legal filing late Wednesday.
WHEC Rochester's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
The Food and Drug Administration (FDA) won’t publish its safety review of the abortion drug mifepristone until March, it disclosed in a Wednesday court filing, adding that it won’t impose any new restrictions on the pill before that point.
The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year. The FDA gave a court-ordered update on its progress in a legal filing late Wednesday.
WASHINGTON (AP) — The Food and Drug Administration says its ongoing safety review of the nation’s main abortion pill will continue into next year, a timeline that was quickly condemned by abortion opponents hoping to see the drug’s use curtailed.
The FDA says its ongoing safety review of the nation's main abortion pill will continue into next year, a timeline quickly condemned by abortion rights foes hoping to see the drug's use curtailed.
“The administration is delaying this report because attacks on medication abortion will backfire with voters, but extremists will try to ban abortion as soon as the election is over.”
The FDA expects to obtain results from a major safety study by mid-December, with a final report completed no later than March. Only then will the agency determine whether changes to its existing regulations are necessary.
Identical headlines usually mean shared wire copy. They are counted as separate articles but are not independent confirmation.
